Next Article in Journal
Antibiotic Residues and Antibiotic-Resistant Bacteria in Pig Slurry Used to Fertilize Agricultural Fields
Next Article in Special Issue
Predicting Antimicrobial and Other Cysteine-Rich Peptides in 1267 Plant Transcriptomes
Previous Article in Journal
Bacteriocins, Potent Antimicrobial Peptides and the Fight against Multi Drug Resistant Species: Resistance Is Futile?
Previous Article in Special Issue
Designed Antimicrobial Peptides for Topical Treatment of Antibiotic Resistant Acne Vulgaris

Inhibitory Activity of a Scorpion Defensin BmKDfsin3 against Hepatitis C Virus

State Key Laboratory of Virology, Modern Virology Research Center, College of Life Sciences, Wuhan University, Wuhan 430072, China
Zoology Department, Al-Azhar University, Assuit 71524, Egypt
Zoology Department, Faculty of Science, Suez Canal University, Ismailia 41522, Egypt
Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Avenida de Universidade, Taipa, Macau 999078, China
Hubei Province Engineering and Technology Research, Center for Fluorinated Pharmaceuticals, Wuhan University, Wuhan 430072, China
Author to whom correspondence should be addressed.
These authors contributed equally.
Received: 17 December 2019 / Revised: 12 January 2020 / Accepted: 14 January 2020 / Published: 17 January 2020
(This article belongs to the Special Issue Antibacterial Peptides)
Hepatitis C virus (HCV) infection is a major worldwide health problem which can cause chronic hepatitis, liver fibrosis and hepatocellular carcinoma (HCC). There is still no vaccine to prevent HCV infection. Currently, the clinical treatment of HCV infection mainly relies on the use of direct-acting antivirals (DAAs) which are expensive and have side effects. Here, BmKDfsin3, a scorpion defensin from the venom of Mesobuthus martensii Karsch, is found to dose-dependently inhibit HCV infection at noncytotoxic concentrations and affect viral attachment and post-entry in HCV life cycle. Further experimental results show that BmKDfsin3 not only suppresses p38 mitogen-activated protein kinase (MAPK) activation of HCV-infected Huh7.5.1 cells, but also inhibits p38 activation of Huh7.5.1 cells stimulated by tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β) or lipopolysaccharide (LPS). BmKDfsin3 is also revealed to enter into cells. Using an upstream MyD88 dimerization inhibitor ST2345 or kinase IRAK-1/4 inhibitor I, the inhibition of p38 activation represses HCV replication in vitro. Taken together, a scorpion defensin BmKDfsin3 inhibits HCV replication, related to regulated p38 MAPK activation. View Full-Text
Keywords: scorpion defensin; Hepatitis C virus (HCV); p38 scorpion defensin; Hepatitis C virus (HCV); p38
Show Figures

Figure 1

MDPI and ACS Style

Cheng, Y.; Sun, F.; Li, S.; Gao, M.; Wang, L.; Sarhan, M.; Abdel-Rahman, M.A.; Li, W.; Kwok, H.F.; Wu, Y.; Cao, Z. Inhibitory Activity of a Scorpion Defensin BmKDfsin3 against Hepatitis C Virus. Antibiotics 2020, 9, 33.

AMA Style

Cheng Y, Sun F, Li S, Gao M, Wang L, Sarhan M, Abdel-Rahman MA, Li W, Kwok HF, Wu Y, Cao Z. Inhibitory Activity of a Scorpion Defensin BmKDfsin3 against Hepatitis C Virus. Antibiotics. 2020; 9(1):33.

Chicago/Turabian Style

Cheng, Yuting, Fang Sun, Songryong Li, Minjun Gao, Luyao Wang, Moustafa Sarhan, Mohamed A. Abdel-Rahman, Wenxin Li, Hang F. Kwok, Yingliang Wu, and Zhijian Cao. 2020. "Inhibitory Activity of a Scorpion Defensin BmKDfsin3 against Hepatitis C Virus" Antibiotics 9, no. 1: 33.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop